DURECT (DRRX)
(Delayed Data from NSDQ)
$1.67 USD
-0.01 (-0.30%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $1.67 +0.01 (0.30%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
DURECT Corporation [DRRX]
Reports for Purchase
Showing records 61 - 80 ( 143 total )
Company: DURECT Corporation
Industry: Medical - Drugs
2Q Recap: Four Potential Value Inflection Points in 2H19; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Gilead License Agreement Brings Strong Validation and Economics; Focus Remains on DUR-928
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
POSIMIR PDUFA December 27; 2H19 Readouts for DUR-928 May Represent Inflection Point; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Company: DURECT Corporation
Industry: Medical - Drugs
DUR-928 Advances to Top Dose Cohort in Alcoholic Hepatitis Trial; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Company: DURECT Corporation
Industry: Medical - Drugs
1Q19 Recap; Preliminary DUR-928 Data in Alcoholic Hepatitis Is Compelling; Potential Phase 3 in 2020; Raise PT to $3.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
KOL Call Outlines Rationale for DUR-928 in the Treatment of NASH; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Data Readouts From Two New Clinical Trials of DUR-928 in 2H19; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Company: DURECT Corporation
Industry: Medical - Drugs
4Q Recap; Expecting Multiple Data Readouts in Three Indications for DUR-928; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
POSIMIR Back on the Regulatory Track With Planned Response to CRL; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Company: DURECT Corporation
Industry: Medical - Drugs
DURECT Accelerates DUR-928 NASH Development Timelines; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
3Q Recap; Accelerating Enrollment of Alcoholic Hepatitis Trial; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Company: DURECT Corporation
Industry: Medical - Drugs
CFO Transition Provides Stability and Continuity; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: DURECT Corporation
Industry: Medical - Drugs
2Q18 Recap: Interim Data on DUR-928 Expected by Year End; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
PERSERIS Approval Is Nice; But Our Thesis Remains Focused on DUR-928; Adjust PT to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E